REMAP-CAP (IL-6)
Tocilizumab or Sarilumab in Critically Ill COVID-19
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 803 critically ill ICU COVID-19 patients within 24 h of organ support, tocilizumab or sarilumab improved organ-support-free days and hospital survival versus control.
N
803
Design
Adaptive platform RCT (REMAP-CAP)
Endpunkt
Organ-support-free days at 21 days
Relevanz
2
ErgebnisMedian organ-support-free days 10 (tocilizumab) and 11 (sarilumab) vs 0 (control); adjusted cumulative OR 1.64 (95% CrI 1.25-2.14) and 1.76 (95% CrI 1.17-2.91). Pooled 90-day survival HR 1.61 (95% CrI 1.25-2.08).
REMAP-CAP Investigators. N Engl J Med. 2021;384(16):1491-1502. 10.1056/NEJMoa2100433
Diskussion & Kritik
Together with RECOVERY-Toci, the basis for routine IL-6 blockade in deteriorating COVID-19.